Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
CA2(Carbonic anhydrase II) | 1 |
Target |
Mechanism CA2 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date28 Sep 2001 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NaPi-2b inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date09 Oct 2015 |
Sponsor / Collaborator |
Start Date09 Dec 2014 |
Sponsor / Collaborator |
Start Date16 May 2012 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Sultiame ( CA2 ) | Sleep Apnea, Obstructive More | Clinical |
Orellanine | Kidney Neoplasms More | Preclinical |
211-astatine-MX35 F(ab')2(Memorial Sloan-Kettering Cancer Center) ( NaPi-2b ) | Ovarian Cancer More | Pending |